A 2,700person realworld study presented at the 2025 European Congress on Obesity showed an average 16% weightloss over 64 weeks at microdose levels of semaglutide
BPC-157 and mazdutide received tentative B ratings based on only 2 tests each
But weight loss isnt just fat loss
Small, frequent sips of flavored or chilled water make it easier to stay hydrated without exacerbating gastrointestinal symptoms
2 Wegovy pill was approved on December 22, 2025 and is used with a reduced calorie diet and increased physical activity for adults with obesity, or with overweight who also have weight-related medical problems, to help them lose weight and keep it off
Research Evidence Comparison# Retatrutide Research# The pivotal Phase 2 trial (Jastreboff et al., NEJM 2023) enrolled 338 adults with obesity and demonstrated weight reductions of up to 24.2% at 48 weeks